GALAXY SUPER SPECIALITY ( EMEDKIT )
GALAXY SUPER SPECIALITY ( EMEDKIT )
Rajinder Nagar, New Delhi, Delhi
GST No. 07AASFG6985C1ZW
TrustSEAL Verified
Call 08043258671 0% Response Rate
SEND EMAIL

Entecavir Tablet

Wholesale Trader of a wide range of products which include entecavir tablet, x-vir entecavir 0.50 mg and x-vir entecavir tablets 1 mg.

Entecavir Tablet

Entecavir Tablet
  • Entecavir Tablet
Get Best Quote
Approx. Price: Rs 1,300 / 1 packGet Latest Price
We are offering to our clients a wide assortment of Entecavir Tablet. Our provided range of these products is mainly used to treat chronic hepatitis B infection in adults and children 2 years and older with active viral replication and evidence of active disease and also used to prevent HBV re infection after liver transplant and to treat HIV patients infected with HBV.

Features:


  • Precise composition
  • Longer shelf life
  • Highly effective

Other Details:


  • Entecavir is mainly used to treat chronic hepatitis B infection in adults and children 2 years and older with active viral replication and evidence of active disease
  • It is also used to prevent HBV reinfection after liver transplant and to treat HIV patients infected with HBV
  • Entecavir is weakly active against HIV, however it is not recommended for use in HIV-HBV co-infected patients without a fully suppressive anti-HIV regimen as it may select for resistance to and emtricitabine in HIV
  • 0.5
Request
Callback
Yes! I am interested

X-VIR Entecavir 0.50 Mg

X-VIR Entecavir 0.50 Mg
  • X-VIR Entecavir 0.50 Mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size30

Brand Name: X-VIR
Strengths: 0.5mg
Manufacturer: Natco Pharma Ltd
Generic Name: Entecavir

Description

X-VIR (entecavir) is referred to as the nucleoside analogs of guanosine. A drug with high antiviral activity. Entecavir is approved for the treatment of chronic hepatitis B. entecavir has advantages over interferons - it is well tolerated, it is taken orally, and the risk of developing resistance to treatment with entecavir is minimal, which in turn reduces the risk of relapse. Nucleoside analogs, including X-VIR, can be used for fibrosis and cirrhosis of the liver.

Orally admission should be done on an empty stomach (2 hours before or 2 hours after meals). With compensated liver damage, the recommended dose is 500 mg1 time per day.

With a decompensated lesion of the liver noted in the patient, or in case of resistance to Lamivudine, X-VIR is prescribed at a dose of 1 mg per day (per 1 dose).
In patients with renal insufficiency, dose adjustment is possible. With QC less than 50 ml/min or when a patient is required hemodialysis, including peritoneal, intervals between doses can be from 48 hours to 5-7 days (determined by the clearance of creatinine).

Analogs of nucleosides (including entecavir) can lead to lactic acidosis and severe hepatomegaly with steatosis (in some cases fatal). This side effect was most often observed in patients. With lactacidosis general fatigue, nausea, vomiting, abdominal pain, sudden weight loss, shortness of breath, rapid breathing, and muscle weakness are noted.

After the termination of antiviral therapy, there may be an exacerbation of hepatitis. To prevent this, after the end of the entecavir administration, liver function in the patient should be monitored. Usually, this side effect was without serious consequences, but in some cases, exacerbations can be severe.

entecavir is not intended for HIV treatment. Prescribing the drug to HIV patients who do not receive antiretroviral therapy can lead to the emergence of resistant strains of HIV.

The development of serious side effects is possible if the patient has decompensated liver damage. In this case, the risk of lactic acidosis and the hepatorenal syndrome is quite high. The condition of such patients during treatment should be carefully monitored and all appropriate laboratory tests performed.
In patients resistant to Lamivudine, the risk of developing resistance of the hepatitis B virus to entecavir is increased.

X-VIR does not reduce the risk of transmission of hepatitis B, appropriate precautions should be observed.
Admission Entecavir simultaneously with drugs that are excreted by the kidneys, or affect the function of the kidney, must be accompanied by careful medical supervision. In this case, since Entecavir is excreted mainly by the kidneys, an increased concentration of entecavir in the blood may be noted.

The drug is contraindicated in pregnant women. The use of Entecavir during pregnancy is justified only in special cases. During treatment with entecavir, breastfeeding should be discontinued.

 X-vir (Analog Baracluda) (Entecavir) refers

 to new drugs from the group of nucleoside analogs for the treatment of chronic HBV infection. It is a carboxylic analog of 2'-deoxyguanosine, rapidly transforming into a cell in an active form, suppressing the replication of HBV in all its three stages - initiation, elongation, termination.

Request
Callback
Yes! I am interested

X-VIR Entecavir Tablets 1 Mg

X-VIR Entecavir Tablets 1 Mg
  • X-VIR Entecavir Tablets 1 Mg
Ask For Price
Product Price :Get Latest Price
Brand Name: X-VIR
Strengths: 1 Mg
Manufacturer: Natco Pharma Ltd
Generic Name: Entecavir
Description

X-VIR (entecavir) is referred to as the nucleoside analogs of guanosine. A drug with high antiviral activity. Entecavir is approved for the treatment of chronic hepatitis B. entecavir has advantages over interferons - it is well tolerated, it is taken orally, and the risk of developing resistance to treatment with entecavir is minimal, which in turn reduces the risk of relapse. Nucleoside analogs, including X-VIR, can be used for fibrosis and cirrhosis of the liver.

Orally admission should be done on an empty stomach (2 hours before or 2 hours after meals). With compensated liver damage, the recommended dose is 500 mg1 time per day.

With a decompensated lesion of the liver noted in the patient, or in case of resistance to Lamivudine, X-VIR is prescribed at a dose of 1 mg per day (per 1 dose).

In patients with renal insufficiency, dose adjustment is possible. With QC less than 50 ml/min or when a patient is required hemodialysis, including peritoneal, intervals between doses can be from 48 hours to 5-7 days (determined by the clearance of creatinine).

Analogs of nucleosides (including entecavir) can lead to lactic acidosis and severe hepatomegaly with steatosis (in some cases fatal). This side effect was most often observed in patients. With lactacidosis general fatigue, nausea, vomiting, abdominal pain, sudden weight loss, shortness of breath, rapid breathing, and muscle weakness are noted.

After the termination of antiviral therapy, there may be an exacerbation of hepatitis. To prevent this, after the end of the entecavir administration, liver function in the patient should be monitored. Usually, this side effect was without serious consequences, but in some cases, exacerbations can be severe.

entecavir is not intended for HIV treatment. Prescribing the drug to HIV patients who do not receive antiretroviral therapy can lead to the emergence of resistant strains of HIV.

The development of serious side effects is possible if the patient has decompensated liver damage. In this case, the risk of lactic acidosis and the hepatorenal syndrome is quite high. The condition of such patients during treatment should be carefully monitored and all appropriate laboratory tests performed.
In patients resistant to Lamivudine, the risk of developing resistance of the hepatitis B virus to entecavir is increased.

X-VIR does not reduce the risk of transmission of hepatitis B, appropriate precautions should be observed.
Admission Entecavir simultaneously with drugs that are excreted by the kidneys, or affect the function of the kidney, must be accompanied by careful medical supervision. In this case, since Entecavir is excreted mainly by the kidneys, an increased concentration of entecavir in the blood may be noted.

The drug is contraindicated in pregnant women. The use of Entecavir during pregnancy is justified only in special cases. During treatment with entecavir, breastfeeding should be discontinued.

 X-vir (Analog Baracluda) (Entecavir) refers

 to new drugs from the group of nucleoside analogs for the treatment of chronic HBV infection. It is a carboxylic analog of 2'-deoxyguanosine, rapidly transforming into a cell in an active form, suppressing the replication of HBV in all its three stages - initiation, elongation, termination.

Request
Callback
Yes! I am interested
X

Explore More Product



Reach Us
Jasminder Singh (CEO)
GALAXY SUPER SPECIALITY ( EMEDKIT )
Ground Floor, Old Rajinder Nagar
New Delhi - 110060, Delhi, India


Call Us


Send E-mailSend SMS